|
Report Date : |
27.02.2012 |
IDENTIFICATION DETAILS
|
Name : |
ANTIBIOTICE SA |
|
|
|
|
Registered Office : |
Valea Lupului 1 707410 Iasi, jud. Iasi |
|
|
|
|
Country : |
Romania |
|
|
|
|
Financials (as on) : |
30.09.2011 |
|
|
|
|
Year of Establishment : |
1953 |
|
|
|
|
Com. Reg. No.: |
J22/285/1991 |
|
|
|
|
Legal Form : |
Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture of basic pharmaceutical products |
|
|
|
|
No. of Employees : |
1454 |
RATING & COMMENTS
|
MIRAs Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
EUR 2.500.000,00 |
|
Status : |
Good |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
Romania |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
|
|
|
Insolvency Information: |
According to available information sources
the company is not in a insolvency/preliminary/debt regulation proceeding. |
|
|
|
Maximum Credit: |
EUR 2.500.000,00 |
|
|
|
|
|
Payment Practices: |
According to our
experiences payments are made regularly. |
|
|
|
Further Rating Information: |
Researched company
is categorized as a big company. |
|
|
|
Debt Collection: |
EUR 404.379,80 (Invoice date: 05.09.2008) |
|
|
|
Established: |
1953 |
|
|
|
Registration: |
No. J22/285/1991 |
|
|
|
Legal Form: |
joint stock company |
|
|
|
History: |
1953 - 1959 |
|
|
|
Capital: |
|
|||||||||||||||||||||||
|
|
|
Shareholders: |
|
|
|
|
Management: |
|
|
|
|
Person functions in other companies: |
|
||||||||||||||||
|
|
|
|
|
Subject of
Operation: |
NACE |
|
|
|
Company Development: |
Positive business development |
|
|
|
Key Data:
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
Workforce: |
|
|
|
|
Exports: |
The biggest drugs exporters : Europharm, Sandoz, Actavis, Antibiotice
Iasi |
|
|
|
|
|
Financials:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
Approximate Exchange Rates: |
2011: 4,2379 RON = 1 EUR |
|
|
|
Financial Comments: |
Source of financials for 30.09.2011:
Bucharest Stock Exchange. |
|
|
|
Investments: |
Currently, the company has an extensive
investment program along 5 years, with a total of 20.3 million euros. |
|
|
|
Bankers: |
ALPHA BANK
ROMANIA SA SUCURSALA IASI |
|
Ratios:
|
|
General Information: |
The subject company is listed on the first
tier of the Bucharest Stock Exchange from: 16.04.1997 |
|
|
|
Press Releases: |
Antibiotice closed 2011 with a preliminary
net profit of 20 million RON (4,7 million euro), with 60% higher than the one
registered in 2010, after a business growth of 15,7% last year, reaching
281,9 million RON (66,5 million euro). (Ziarul Financiar, 14.02.2012).
(Ziarul Financiar, 14.02.2012) |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.06 |
|
|
1 |
Rs.77.19 |
|
Euro |
1 |
Rs.65.57 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SCs credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.